Novo Nordisk has reduced their growth forecasts in it's latest earnings report for the third quarter.
The Danish pharmaceutical giant, best known for producing diabetes and obesity management drugs Ozempic and Wegovy, lowered its full-year guidance for the fourth time this year in the Q3 report.
Sales growth figures were reduced from a range of 8-14% down to 8-11%, along with operating profit growth expectations going from 4-10% to 4-7%.
Competition for the weight loss drug market and pricing pressures were the driving factors for these new lowered forecasts.
Wegovy sales were up 18% year-on-year to the tune of 20.35 billion Danish kroner in the three months to September, and operating profit for the first nine months of this year came in 10% higher compared to the same period the year prior, at 95.9 billion kroner.
“While we delivered robust sales growth in the first nine months of 2025, the lower growth expectations for our GLP-1 treatments have led to a narrowing of our guidance,” said Mike Doustdar, president and CEO.
“We aim to accelerate on all fronts to be able to compete better in dynamic and increasingly competitive markets.”
